drugset / Trial / NCT01092585
Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH
NaSingle-groupOpen-labelTreatment
Summary
Tesetaxel is an orally administered chemotherapy agent of the taxane class. This study is being undertaken to evaluate the efficacy and safety of tesetaxel administered as second-line therapy to patients with advanced melanoma and normal serum lactate dehydrogenase (LDH).
Timeline
- Start
- 2010-02
- Primary completion
- 2012-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tesetaxel | Small molecule | 35 mg | Oral |
| Subject | Tesetaxel | Small molecule | 40 mg | Oral |
| Subject | Tesetaxel | Small molecule | 45 mg | Oral |